APA × LuvionBio
Raising the standard for research-use-only peptide quality — together with the American Peptide Association.
LuvionBio is supporting the American Peptide Association through our Founder’s role as Chairman of the Applied Science and Innovation Committee. The mission: develop a novel, holistic, repeatable, and transparent peptide testing framework that can be adopted across the industry. The goal is to move beyond basic COA metrics and establish a more advanced three-pillar standard focused on safety, peptide quality, and manufacturing discipline.
This work is designed to protect the RUO market as it matures by creating practical, science-based benchmarks for purity, identity, potency, stability, impurity profiling, and batch-to-batch consistency. By pairing traditional analytical testing with functional potency and longitudinal supplier evaluation, we believe the industry can raise quality standards, improve transparency, and create a more credible framework for manufacturers, qualified researchers, and other institutions.
Proof-of-Concept Studies
We’re not just proposing the standard — we’re executing against it. Our first independent, third-party studies put the framework into practice across functional potency and reconstituted-solution stability.
The Proposed Three-Pillar Standard
A scannable reference of the tests proposed under each of three pillars in the APA Voluntary Peptide Quality Standard (Working Draft v1.0, authored by LuvionBio LLC on behalf of the American Peptide Association). For each test: what it confirms, and how it aligns with established pharmaceutical analytical practice.
PILLAR 1
Safety
Non-negotiable safety tests for any reagents intended for high quality research.
| Test | What It Confirms | Pharma / FDA Alignment |
|---|---|---|
| Sterility USP <71> | No viable bacteria or fungi in the vial. | Compendial USP method; a baseline expectation for parenteral-grade material and biologics. |
| Bacterial Endotoxin (BET) USP <85> · LAL or rFC | Endotoxin below an established safety limit. | Recognized release test under USP <85>; rFC accepted by FDA and EP/USP. |
| Bioburden / Microbial Limits USP <61> & <62> | Pre-sterilization microbial load within spec; covers fungi and yeast. | Compendial method underpinning USP <1111> microbial quality expectations. |
| Subvisible Particulates USP <788> | Particulate count below recognized thresholds. | USP <788> is the FDA-recognized particulate standard. |
| Visible Particulate Inspection USP <790> | No visually detectable particles in reconstituted solution. | USP <790> pharmacopeial inspection standard. |
| Elemental Impurities ICH Q3D · ICP-MS | 24 toxicologically relevant elements below daily exposure limits. | ICH Q3D is the global regulatory framework; required for USP drug products since 2018. |
| Catalyst Residues ICP-MS targeted (Pd, Ni, Co) | Residual coupling-reagent metals below safety thresholds. | Aligned to ICH Q3D Class 2A/2B element limits. |
| Residual Solvents ICH Q3C · headspace GC | Synthesis solvents (ACN, DMF, TFA, MeOH) below class limits. | ICH Q3C is the FDA-adopted standard for residual solvent control. |
| Mutagenic Impurity Screen ICH M7 · LC-MS targeted | No Class 1/2 DNA-reactive impurities above the TTC threshold. | ICH M7 is the global standard for genotoxic impurity control. |
| Nitrosamine Risk Assessment FDA/EMA framework + LC-MS | Synthetic route evaluated for nitrosamine risk; confirmatory testing where indicated. | Mirrors current FDA/EMA nitrosamine guidance across the small-molecule industry. |
| Counterion Identity & Content Ion Chromatography or 19F-NMR | Counterion (TFA vs. acetate) identified and quantified. | Addresses known TFA concerns; a standard control for peptide drug substance. |
PILLAR 2
Holistic Peptide Quality
Tests that confirm the molecule is what it claims to be, in the amount it claims, behaving the way it should — where the legacy single-purity-number standard breaks down.
| Test | What It Confirms | Pharma / FDA Alignment |
|---|---|---|
| Functional Potency cAMP / EC₅₀ / Eₘₐₓ · cell-based · 4-PL fit | Peptide activates the intended receptor comparably to a recognized reference standard. | Aligns with FDA biosimilar potency guidance, USP <1032>–<1034>, and ICH Q6B; the most demanding Pillar 2 test. |
| Inter-Assay Reproducibility Independent replicate runs, EC₅₀ comparison | Functional potency is reproducible — not a single-run artifact. | Required by USP <1033> for bioassay validation. |
| LC-HRMS/MS Peptide Mapping High-resolution MS with proteolytic mapping | Full sequence correct; no truncations, deletions, insertions, or unintended modifications. | ICH Q6B-aligned identity test; gold-standard sequence confirmation. |
| Amino Acid Analysis (AAA) Acid hydrolysis + chromatographic quantification | Amino acid composition matches the expected ratio for the labeled molecule. | Long-standing USP-recognized identity and quantitation method. |
| Epimerization Assessment Chiral chromatography or epimer-specific MS | Chiral residues retain correct stereochemistry (no D/L scrambling). | Aligned to ICH Q6B impurity expectations; a known peptide failure mode. |
| Oxidation Variants LC-MS targeted | Oxidation of Met, Trp, Cys below specification. | Standard degradation profile per ICH Q1A and Q6B characterization. |
| Deamidation Screening LC-MS targeted | Asn/Gln deamidation impurities below spec. | Standard characterization; a recognized peptide critical quality attribute. |
| HPLC Purity RP-HPLC, UV detection | Chromatographic purity — the legacy COA metric, retained for continuity. | Universal release method; ICH Q6A/Q6B-aligned. |
| Related Substances / Impurity Profiling RP-HPLC with peak ID by MS | Process-related impurities (truncations, side-reaction products) characterized and within spec. | ICH Q3A/Q6B impurity qualification framework. |
| Net Peptide Content (% label claim) Quantitative AAA, Dumas, or MS with internal standard | Vial contains the labeled mass of peptide, net of water, counterion, salt, and solvent. | Basic label-claim verification; routinely missing from RUO peptide COAs. |
| Appearance Visual + UV at multiple wavelengths | Lyophilized cake / solution looks correct — color, clarity, structure. | USP general-chapter expectation for finished product. |
| Reconstitution Behavior Time-to-dissolution, post-reconstitution clarity | Product fully and rapidly dissolves on reconstitution. | Standard finished-product control for lyophilized material. |
| Aggregation / Particle Size Dynamic Light Scattering (DLS) | Peptide is monomeric in solution; no aggregation or higher-order assembly. | USP <1430> and biopharma aggregation control. |
PILLAR 3
Manufacturing Discipline & Control
Tests that confirm the process is consistent batch-to-batch, the container-closure system is intact, and the product remains within specification across its labeled shelf life.
| Test | What It Confirms | Pharma / FDA Alignment |
|---|---|---|
| Water Content Karl Fischer titration | Residual moisture in lyophilized cake within spec — critical for chemical stability. | USP <921> compendial method. |
| Fill Mass Verification Gravimetric sampling | Mass per vial is consistent batch-to-batch and within tolerance. | Basic cGMP fill-process control. |
| pH (post-reconstitution) Calibrated pH electrode | Reconstituted pH at target value, supporting chemical stability. | USP <791> compendial pH method. |
| Osmolality (post-reconstitution) Freezing-point or vapor-pressure osmometry | Reconstituted osmolality within target range. | USP <785> standard release test. |
| Container Closure Integrity (CCIT) Helium leak, vacuum decay, or dye ingress | Vial–stopper–seal system intact; prevents microbial ingress over shelf life. | USP <1207> compendial framework. |
| Extractables & Leachables (E&L) LC-MS / GC-MS targeted screening | Container does not leach silicones, plasticizers, or antioxidants into contents. | USP <1663> / <1664> container-closure qualification. |
| Headspace Analysis Frequency-modulated spectroscopy or GC | Residual O₂ and N₂ in vial headspace within spec. | Critical for oxidation-sensitive peptides; aligned to ICH Q1A. |
| Accelerated Stability ICH Q1A · 25°C/60% RH and 40°C/75% RH | Product remains within spec under accelerated conditions; supports shelf-life prediction. | ICH Q1A is the global standard for stability program design. |
| Long-Term Stability ICH Q1A · labeled storage condition | Product remains within spec across full labeled shelf life. | ICH Q1A long-term arm; supports any labeled expiration date. |
| Freeze-Thaw Stability Cycling study, 3–5 cycles | Product tolerates real-world handling stresses (shipping, refrigerator cycling). | Standard supportive-stability practice; addresses cold-chain risk. |
| Photostability ICH Q1B | Product tolerates expected light exposure during handling and use. | ICH Q1B is the FDA-adopted global standard for photostability testing. |
Learn more about the APA
The American Peptide Association is the industry body advancing standardized, holistic peptide testing.